Investigating the effects of cannabigerol and cannabidiol on fatty liver disease
The therapeutic effect of cannabigerol (CBG) with or without cannabidiol (CBD) in diet-induced non-alcoholic fatty liver disease
This study is looking at how two natural compounds from cannabis, CBG and CBD, might help improve liver health for people with non-alcoholic fatty liver disease (NAFLD) and its more serious form, NASH, by reducing inflammation and damage in the liver.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Northern Colorado NIH-funded |
| Lab location | 1 site (Greeley, United States) |
| Project ID | NIH-10794804 on NIH RePORTER |
What this research studies
This research focuses on the potential therapeutic effects of two non-psychoactive cannabinoids, cannabigerol (CBG) and cannabidiol (CBD), in treating non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). The study aims to evaluate how these cannabinoids can reduce liver inflammation, fibrosis, and damage caused by diet-induced conditions. Using mouse models, the researchers will assess the impact of CBG and CBD on liver health, immune cell behavior, and specific cellular pathways involved in liver function. The findings could provide insights into new treatment options for patients suffering from these chronic liver diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals diagnosed with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
Not a fit: Patients with alcoholic liver disease or those not diagnosed with fatty liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with fatty liver disease, potentially improving liver health and reducing disease progression.
How similar studies have performed: While cannabinoids have shown promise in other inflammatory conditions, the specific application of CBG and CBD for NAFLD/NASH is relatively novel and has not been extensively tested.
Where this research is happening
Greeley, United States
- University of Northern Colorado — Greeley, United States (Active)
Researchers
- Principal investigator: Han, Yuyan — University of Northern Colorado
- Study coordinator: Han, Yuyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.